[{"id":"baa7b37e-cfef-44eb-9956-98a2e2f53335","acronym":"","url":"https://clinicaltrials.gov/study/NCT04993430","created_at":"2021-08-06T13:53:20.485Z","updated_at":"2024-07-02T16:36:20.693Z","phase":"Phase 1","brief_title":"A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT04993430","lead_sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKang (dalpiciclib) • HRS8807"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-11-16"}]